C
Chien-Feng Li
Researcher at National Health Research Institutes
Publications - 218
Citations - 4509
Chien-Feng Li is an academic researcher from National Health Research Institutes. The author has contributed to research in topics: Cancer & Nasopharyngeal carcinoma. The author has an hindex of 34, co-authored 191 publications receiving 3636 citations. Previous affiliations of Chien-Feng Li include Chung Hwa University of Medical Technology & Kaohsiung Medical University.
Papers
More filters
Journal ArticleDOI
Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.
Jen-Chieh Lee,Sheng Yao Su,Sheng Yao Su,Chun A. Changou,Rong-Sen Yang,Keh-Sung Tsai,Michael T. Collins,Eric S. Orwoll,Chung Yen Lin,Shu Hwa Chen,Shyang-Rong Shih,Cheng-Han Lee,Yoshinao Oda,Steven D. Billings,Chien-Feng Li,G. Petur Nielsen,Eiichi Konishi,Fredrik Petersson,Thomas O. Carpenter,Kesavan Sittampalam,Hsuan-Ying Huang,Andrew L. Folpe +21 more
TL;DR: Insight is provided into possible mechanisms underlying the pathogenesis of phosphaturic mesenchymal tumor and imply a central role of the FGF1-FGFR1 signaling pathway.
Journal ArticleDOI
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Hsuan-Ying Huang,Wen Ren Wu,Yu Hui Wang,Jun Wen Wang,Fu-Min Fang,Jen Wei Tsai,Shau Hsuan Li,Hsiao Chin Hung,Shih Chen Yu,Jui Lan,Yow-Ling Shiue,Chung Hsi Hsing,Li-Tzong Chen,Chien-Feng Li +13 more
TL;DR: Findings highlight ASS1 as a novel tumor suppressor in myxofibrosarcomas, with loss of expression linked to promoter methylation, clinical aggressiveness, and sensitivity to ADI-PEG20.
Journal ArticleDOI
A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome.
Hsuan-Ying Huang,Chien-Feng Li,Wen-Wei Huang,Tsung Hui Hu,Ching Nan Lin,Yih Huei Uen,Ching Yeh Hsiung,David Lu +7 more
TL;DR: Remarkable prognostic heterogeneity exists in the high-risk category of the NIH scheme, which is not as effective as the modified criteria in identifying highly lethal GISTs that the authors classified as risk level IV.
Journal ArticleDOI
ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
Jen-Chieh Lee,Chien-Feng Li,Hsuan-Ying Huang,Meijun Zhu,Adrián Mariño-Enríquez,Chung Ta Lee,Wen-Bin Ou,Wen-Bin Ou,Wen-Bin Ou,Jason L. Hornick,Jonathan A. Fletcher +10 more
TL;DR: It is shown that atypical spindle‐cell IMT can utilize the same ALK fusion mechanisms described previously in conventional IMT, whereas in clinically aggressive epithelioid inflammatory myofibroblastic sarcoma a novel recurrent ALK oncogenic mechanism is identified, resulting from fusion with the RRBP1 gene.
Journal ArticleDOI
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC
Hung Jung Wang,Mamata R. Pochampalli,Ling Yu Wang,June X. Zou,Pei Shan Li,Sheng Chieh Hsu,Sheng Chieh Hsu,Bi Juan Wang,Shih Han Huang,Ping Yang,Ping Yang,Joy C. Yang,Cheng Ying Chu,Chia Ling Hsieh,Shian Ying Sung,Chien-Feng Li,Clifford G. Tepper,David K. Ann,David K. Ann,Allen C. Gao,Allen C. Gao,Christopher P. Evans,Yoshihiro Izumiya,Chi Pin Chuu,Wen-Ching Wang,Hongwu Chen,Hsing Jien Kung +26 more
TL;DR: KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells and is validated as a regulator for both androgen-responsive and metabolic genes.